News

IHS Announces Requirements to Increase Access to OUD Treatment

To reduce the high overdose rates among Native communities, new requirements are being implemented giving more access to opioid use disorder treatment.


 

Native American communities have experienced the largest increase in drug overdose deaths of all racial/ethnic groups in the US. Between 1999 and 2015, drug overdose deaths rose > 500%. To help ensure that American Indians and Alaska Natives (AI/AN) get the treatment they need, the Indian Health Service (IHS) has released Special General Memorandum 2019-01: Assuring Access to Medication Assisted Treatment for Opioid Use Disorder . It requires all IHS federal facilities to:

  • Identify opioid use disorder (OUD) treatment resources in their local areas;
  • Create an action plan, no later than Dec. 11, 2019; and
  • Provide or coordinate patient access to medication-assisted treatment (MAT), specifically increasing access to culturally appropriate prevention, treatment, and recovery support services.

MAT is a comprehensive evidence-based approach that combines pharmacologic interventions with substance abuse counseling and culturally sensitive social support.

The IHS has recently taken other steps to further facilitate MAT access in tribal communities. For example, it has added 3 FDA-approved medications to the National Core Formulary: buprenorphine, buprenorphine/naloxone, and injectable naltrexone, all of which relieve withdrawal symptoms and psychological cravings, supporting adherence to treatment and reducing illicit opioid use.

In addition, the IHS has published the Internet Eligible Controlled Substance Provider Designation Policy. This policy, established in 2018, is designed to increase access to treatment for AI/AN who live in rural or remote areas, where it can be difficult to access a provider with the necessary training and Drug Enforcement Administration approval to prescribe buprenorphine in an outpatient or office-based setting. Once approved, IHS, tribal, and urban Indian organization health care providers can prescribe controlled substances for MAT through telemedicine.

In 2018, the IHS also launched a new website ( www.IHS.gov/opioids) to share information about opioids with patients, health care providers, tribal leaders, tribal and urban program administrators, and other community members. The site includes information on approaches to prevent opioid abuse, pain management, recovery tools, and funding opportunities.

Recommended Reading

Marijuana during prenatal OUD treatment increases premature birth
Federal Practitioner
Direct pharmacy dispensing of naloxone linked to drop in fatal overdoses
Federal Practitioner
Racial, economic disparities found in buprenorphine prescriptions
Federal Practitioner
More than 40% of U.K. physicians report binge drinking
Federal Practitioner
Chronic opioid use linked to low testosterone levels
Federal Practitioner
Risk of suicide attempt is higher in children of opioid users
Federal Practitioner
Opioid prescriptions declined 33% over 5 years
Federal Practitioner
Nicotine replacement therapy beats varenicline for smokers with OUD
Federal Practitioner
Medical cannabis laws appear no longer tied to drop in opioid overdose mortality
Federal Practitioner
Co-use of opioids, methamphetamine on rise in rural Oregon
Federal Practitioner